DNA nanotechnology offers an unprecedented level of structural programmability for organizing metallic nanoparticles into precisely defined architectures, providing a powerful platform for plasmonic biosensing. In particular, gold and silver nanoparticles assembled on DNA nanostructures enable nanometer-scale control over interparticle distance, orientation, and spatial symmetry, which directly govern collective plasmonic behaviors and optical signal transduction. This review summarizes recent advances in DNA nanostructure-mediated assembly of metal nanoparticles, with an emphasis on design principles and assembly strategies that enable static and dynamic control of nanoparticle organization. Representative examples are discussed to illustrate how well-defined plasmonic assemblies give rise to tunable optical responses, including localized surface plasmon resonance modulation, chiroptical signals, fluorescence enhancement or quenching, and surface-enhanced Raman scattering. The role of structural programmability and stimulus-responsive reconfiguration in translating molecular recognition events into amplified optical outputs is highlighted in the context of biosensing. Finally, current challenges and future perspectives are outlined, focusing on structural robustness, signal reproducibility, and integration toward practical and multiplexed biosensing platforms.

With the escalating challenges of global warming and the energy crisis, electrocatalytic CO₂ reduction reaction (CO₂RR) has emerged as a promising strategy to mitigate atmospheric CO₂ concentrations while converting it into high-value-added chemicals. Among various CO₂RR catalysts, copper-based materials exhibit unique capabilities for C-C coupling, yet their practical application remains constrained by several limitations: Low selectivity for C₂₊ products (typically <60%); Catalyst instability due to dynamic reconfiguration of active sites under high overpotentials; poor energy efficiency caused by competing hydrogen evolution reactions (HERs), etc. Recent studies demonstrate that nonmetallic heteroatom doping or functionalized ligand incorporation can effectively modulate the electronic structure and surface microenvironment of Cu-based catalysts, thereby enhancing CO₂RR performance. In this review, we comprehensively summarize recent advances in such strategies. We first systematically elucidate the unique advantages of copper-based catalysts as benchmark materials for multi-carbon (C₂₊) product synthesis, along with the current challenges they face. Subsequently, we highlight recent advances in modulating copper-based catalysts through the incorporation of diverse nonmetallic heteroatoms (e.g., N, S, B, P, halogens) or the introduction of functionalized ligands, with a particular focus on mechanistic insights and characterization methods aimed at enhancing C-C coupling efficiency and improving C₂₊ product selectivity. Finally, we present perspectives on the remaining opportunities and challenges in this research field.

Single-walled carbon nanotubes (SWCNTs) feature extraordinary electrical, optical and mechanical properties governed by their unique chiral structures, yet as-synthesized SWCNTs exist as heterogeneous mixtures with severe bundling, which severely restricts their high-performance applications. Over recent decades, tremendous progress has been achieved in the dispersion, chiral sorting and optical sensing of SWCNTs. In this review, we first comprehensively summarize the mainstream dispersion strategies of SWCNTs, including physical dispersion relying on external mechanical forces and non-destructive chemical dispersion such as polymer wrapping, DNA wrapping, surfactant adsorption and aromatic small molecule π–π stacking. Subsequently, we systematically introduce several representative chiral sorting techniques, namely aqueous two-phase extraction (ATPE), density gradient ultracentrifugation (DGU), gel column chromatography (GCC), and polymer-based wrapping approach. Furthermore, we highlight the research advances of SWCNT-based near-infrared (NIR) fluorescent sensors for the detection of metal ions, neurotransmitters, nucleic acids, proteins and viruses, as well as their applications in in vivo biological detection of plants and animals. Finally, we discuss the existing challenges in the scalable preparation of chirality-pure SWCNTs, sensor stability and in vivo applications, and prospect the future development directions toward practical translation. This review aims to provide a systematic reference for promoting the development and application of SWCNTs in advanced optical biosensing.

Framework nucleic acids (FNAs) are a class of nucleic acid-based nanostructures characterized by their unique precise structures, excellent biocompatibility and stability, robust loading capacity, and distinctive distribution and metabolic behaviors. They are widely applied in frontier fields such as nanodevices, biosensing, and drug delivery. In recent years, research on FNAs has gradually developed from the design and synthesis of nucleic acid nanostructures to practical applications, particularly in providing precise nanocontainers for heterogeneous molecular drugs such as small molecules, peptides, and proteins. Acting as a drug delivery system, FNA nanocontainers could be utilized to address multiple issues inherent in the application of heterogeneous molecular drugs, including hydrophobicity, affinity, and stability. However, they also face challenges such as low drug carrier capacity, potential immunogenicity, and insufficient long-term stability in vivo, necessitating the development of new strategies. This article focuses on composite drugs of small molecules, peptides, and proteins carried by FNAs, elucidates the design principles of FNA carriers, the interaction modes between FNAs and drug molecules, and the physicochemical properties and biological effects/efficacy of FNA–drug complexes, and summarizes the structure–activity relationship patterns. Furthermore, obstacles limiting clinical transformation are proposed to provide beneficial suggestions for the future development of FNA-based drugs.